CO.DON AG announced that it has achieved the next milestone on the path of its international business expansion: with the arrival of the first biopsy, routine production of the EU- approved pharmaceutical officially started at the Leipzig site. After the project start in 2017, the completion of the plant construction and subsequent time-consuming validation and qualification phase, one of the largest projects in the company's history was completed on time and on budget and transferred into routine. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells. CO.DON's method is currently used in over 200 clinics in Germany and more than 16,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorization for this product, followed by the marketing authorization for Switzerland in March 2019. At the Leipzig site, CO.DON has built one of the largest facilities for the production of human cells on an industrial scale for in-house and contract manufacturing.